Skip to main content
GKOSGlaukos CorporationSell5.5·$244.88
SellModerate Confidence
Investment thesis

Glaukos is a high-growth glaucoma device franchise (58% YoY growth, Rule of 40 at 66) but trades at a very high multiple, above the analyst target, with heavy product and US concentration.

Thesis pillars

  • Elite Growth Profile→Stable
  • Expensive Valuation→Stable
  • Product Concentration↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026, based on the 10-K filed Feb 23, 2026

Full reasoning →

Open full analysis

Glaukos Corporation (GKOS) Stock Analysis

SellVALUE-TRAP 2/5GrowthModerate Confidence

Healthcare · Medical Devices

Sell if holding. At $244.88, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%).

Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease, with 74% of 2025 net sales from U.S. customers. The glaucoma franchise — iStent devices and iDose TR — accounted for approximately 83% of net sales; iLink... Read more

$244.88-13.4% A.UpsideScore 5.5/10#31 of 62 Medical Devices
QualityF-score8 / 9FCF yield0.36%
Stop $227.74Analyst target $212.15(reached)A.R:R -0.9:1
Analyst consensus$243.85-0.4%13 analysts with price targets
$244.88price
$243.85mean
$225
$270

Sell if holding. At $244.88, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About Glaukos Corporation

About Glaukos Corporation

Glaukos' glaucoma franchise — the iStent family (first FDA-cleared in 2012) and the iDose TR intracameral travoprost implant (FDA-approved December 2023) — accounted for approximately 83% of 2025 net sales, with the iLink corneal cross-linking platform contributing approximately 17%. U.S. customers represented 74% of net sales in 2025 and international customers 26%, with no single customer exceeding 10% of total net sales. Epioxa, an epi-on corneal cross-linking therapy, received FDA approval in October 2025 with commercial launch planned for early 2026.

Glaukos generates revenue through a U.S. direct sales force targeting ambulatory surgery centers, hospitals, and private practices, and through direct subsidiaries and distribution partners in Australia, Brazil, Canada, Germany, Japan, and the United Kingdom. The iStent family and iDose TR are reimbursed by Medicare and major private payers; physician fee reimbursement for iDose TR continues to be standardized across Medicare Administrative Contractors via temporary CPT codes. Manufacturing for the iStent and iDose product lines is concentrated at a sole campus in San Clemente, California, and the company relies on sole-source third-party suppliers for certain device and drug components. Glaukos competes in glaucoma primarily against Alcon, AbbVie, Sight Sciences, and Iantrek, and holds the only FDA-approved bio-activated pharmaceutical for keratoconus.

Show full overview

Local coverage determinations finalized by five of seven Medicare Administrative Contractors in November 2024 confirmed non-coverage for surgical MIGS procedures performed in combination with other surgical MIGS procedures, disrupting traditional ordering patterns and potentially weighing on U.S. glaucoma revenue through 2025 and beyond. The iDose platform's longer-term trajectory depends on Phase 2b/3 trial outcomes for the second-generation iDose TREX and the Phase 3 iDose TRIO program; if those trials fail to support expanded indications, the franchise may remain confined to the first-generation travoprost implant in open-angle glaucoma and ocular hypertension.

See also: Healthcare · Medical Devices

From Glaukos Corporation's most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Oct 28, 2026

Recent Developments — Glaukos Corporation

Latest item Oct 28, 2026 · Generated 2026-11-17T11:47:25Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 16, 202791d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (3/4)
Strong growth profile
Recent Analyst detected in news
Risks
Concentration risk — Geographic: U.S. customers (74.0%)
Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%)
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)—
P/E (Fwd)174.9
Mkt Cap$14.5B
EV/EBITDA-712.5
Profit Mgn-24.6%
ROE-22.8%
Rev Growth58.0%
Beta0.68
DividendNone
Analysts with ratings20

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.97bearish
IV71%elevated

Concentration Risks(10-K Item 1A)

  • HIGHGeographicU.S. customers74%
    10-K Item 1: 'sales to U.S. and international customers accounted for 74% and 26% of our net sales, respectively'
  • HIGHProductiStent family and iDose TR glaucoma franchise83%
    10-K Item 1: 'our iStent family of products, iDose TR, and related glaucoma accessories accounted for approximately 83% of our net sales'
  • HIGHSuppliersole manufacturing campus in San Clemente
    10-K Item 1A: 'Our sole manufacturing location for our iStent and iDose products is an approximately 120,000 square foot campus located in San Clemente, California'
  • HIGHSuppliersole third-party component suppliers
    10-K Item 1A: 'we rely on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models, the iStent infinite, the iDose TR'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Forward Pe
1.0
Analyst Target
3.0
Peg Ratio
6.3
Forward P/E: 174.9xPEG: 1.19Expensive valuation
GatesA.R:R -0.9=NEGATIVEMomentum 4.9<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.9>=4.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY 91d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
72 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $168.00Resistance $255.19

Price Targets

A.Upside-13.4%
A.R:R-0.9:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (-13.4% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-02-16 (91d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is GKOS stock a buy right now?

Sell if holding. At $244.88, A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $227.74. Score 5.5/10, moderate confidence.

What is the GKOS stock price target?

Analyst target $212.15 reached (−13.4% from $244.88); no take-profit level is published. Prior stop was $227.74. Stop-loss: $227.74.

What are the risks of investing in GKOS?

Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%); Analyst target reached - limited upside remaining.

Is GKOS overvalued or undervalued?

Glaukos Corporation trades at a P/E of N/A (forward 174.9). TrendMatrix value score: 2.1/10. Verdict: Sell.

What do analysts say about GKOS?

20 analysts rate GKOS, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $244.

What does Glaukos Corporation do?Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease,...

Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease, with 74% of 2025 net sales from U.S. customers. The glaucoma franchise — iStent devices and iDose TR — accounted for approximately 83% of net sales; iLink corneal cross-linking therapies contributed approximately 17%. iDose TR was FDA-approved in December 2023; Epioxa, approved in October 2025, is planned for commercial launch in early 2026.

Related stocks: PODD (Insulet Corporation) · MDT (Medtronic plc.) · ENOV (Enovis Corporation) · DXCM (DexCom, Inc.) · IRTC (iRhythm Holdings, Inc.)
Home › Stocks › GKOS

Latest news

Latest News

GuruFocus48d ago
Finance.yahoo.com111d ago
Yahoo Finance111d ago
GuruFocus111d ago
Quiver Quantitative111d ago
Marketscreener.com111d agoEarnings
TradingKey111d ago
Yahoo Finance20d ago
Yahoo Finance20d agoEarnings
StocksToTrade20d ago
Timothy Sykes20d ago
Yahoo Finance20d agoEarnings
Quiver Quantitative20d ago
Marketscreener.com20d agoEarnings
GuruFocus55d ago
Benzinga55d ago
Finance.yahoo.com55d ago
Yahoo Finance55d ago
TradingKey153d ago
GuruFocus153d agoAnalyst
Loading more...